

GLAXOSMITHKLINE PLC
Form 6-K
August 23, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending August 2012

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of a change in the interests of a Person Discharging Managerial Responsibility (PDMR), in the Ordinary Shares (ORDs) of GlaxoSmithKline plc as a result of an award made under the GlaxoSmithKline 2009 Share Value Plan (SVP) on 22 August 2012 as follows:

| | |
|-------------|-----------------|
| PDMR | Ordinary Shares |
| Mrs V Whyte | 13,070 |

The GlaxoSmithKline 2009 Share Value Plan award was based on an Ordinary Share price of £14.425 per Share, (the closing middle market price of an Ordinary Share in GlaxoSmithKline plc on 22 August 2012).

The Company and the Person Discharging Managerial Responsibility were advised of this transaction on 23 August 2012.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary

23 August 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 23, 2012

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc